{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:28:06Z","timestamp":1787311686016,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40256-026-00817-5","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:17:22Z","timestamp":1784794642000},"page":"603-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1583-2549","authenticated-orcid":false,"given":"Zeyad","family":"Elariny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8029-701X","authenticated-orcid":false,"given":"Omar","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7658-8051","authenticated-orcid":false,"given":"Mohamad Ashraf","family":"Salaheldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7978-3702","authenticated-orcid":false,"given":"Adham","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4520-7190","authenticated-orcid":false,"given":"Farida","family":"Rabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Mohamed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9316-1770","authenticated-orcid":false,"given":"Mohamed","family":"Harish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9982-8744","authenticated-orcid":false,"given":"Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9137-6922","authenticated-orcid":false,"given":"Selim Ahmed","family":"Eliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7380-0414","authenticated-orcid":false,"given":"Mohammad","family":"Elshorbagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3560-8249","authenticated-orcid":false,"given":"Sara","family":"ElHarouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4528-795X","authenticated-orcid":false,"given":"Ahmed","family":"Abdelmeguid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1282-440X","authenticated-orcid":false,"given":"Retaj","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7959-9316","authenticated-orcid":false,"given":"Omnia Azmy","family":"Nabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"2 Pt 2","key":"817_CR1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1161\/01.hyp.37.2.350","volume":"37","author":"FC Luft","year":"2001","unstructured":"Luft FC. Twins in cardiovascular genetic research. Hypertension. 2001;37(2 Pt 2):350\u20136. https:\/\/doi.org\/10.1161\/01.hyp.37.2.350. (PubMed PMID: 11230299).","journal-title":"Hypertension"},{"issue":"6","key":"817_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/01.HYP.26.6.919","volume":"26","author":"R Fagard","year":"1995","unstructured":"Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, et al. Heritability of conventional and ambulatory blood pressures: a study in twins. Hypertension. 1995;26(6):919\u201324. https:\/\/doi.org\/10.1161\/01.HYP.26.6.919.","journal-title":"Hypertension"},{"issue":"10010","key":"817_CR3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","volume":"386","author":"MH Forouzanfar","year":"1990","unstructured":"Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 1990;386(10010):2287\u2013323. https:\/\/doi.org\/10.1016\/S0140-6736(15)00128-2.","journal-title":"Lancet"},{"issue":"2","key":"817_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"1990","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115\u00a0mm Hg, 1990\u20132015. JAMA. 1990;317(2):165. https:\/\/doi.org\/10.1001\/jama.2016.19043.","journal-title":"JAMA"},{"issue":"7","key":"817_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.7.844","volume":"291","author":"CS Fox","year":"2004","unstructured":"Fox CS. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844. https:\/\/doi.org\/10.1001\/jama.291.7.844.","journal-title":"JAMA"},{"key":"817_CR6","unstructured":"Mayo Clinic Staff. High blood pressure (hypertension)\u2014symptoms & causes [Internet]. 2024. https:\/\/www.mayoclinic.org\/diseases-conditions\/high-blood-pressure\/symptoms-causes\/syc-20373410."},{"issue":"33","key":"817_CR7","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"11","key":"817_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802. https:\/\/doi.org\/10.1038\/s41569-021-00559-8.","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"817_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","volume":"336","author":"LJ Appel","year":"1997","unstructured":"Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117\u201324. https:\/\/doi.org\/10.1056\/NEJM199704173361601.","journal-title":"N Engl J Med"},{"issue":"1","key":"817_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","volume":"344","author":"FM Sacks","year":"2001","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001;344(1):3\u201310. https:\/\/doi.org\/10.1056\/NEJM200101043440101.","journal-title":"N Engl J Med"},{"issue":"19","key":"817_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.19.2455","volume":"294","author":"LJ Appel","year":"2005","unstructured":"Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294(19):2455. https:\/\/doi.org\/10.1001\/jama.294.19.2455.","journal-title":"JAMA"},{"issue":"2","key":"817_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","volume":"170","author":"JA Blumenthal","year":"2010","unstructured":"Blumenthal JA. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170(2):126. https:\/\/doi.org\/10.1001\/archinternmed.2009.470.","journal-title":"Arch Intern Med"},{"issue":"38","key":"817_CR13","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"817_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2024.200341","volume":"23","author":"E Badila","year":"2024","unstructured":"Badila E. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension\u2014how practical is it for clinical practice? Int J Cardiol Cardiovasc Risk Prev. 2024;23:200341. https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200341.","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"11","key":"817_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s40265-025-02229-2","volume":"85","author":"AFG Cicero","year":"2025","unstructured":"Cicero AFG, Tocci G, Avagimyan A, Penson P, Nardoianni G, Perone F, et al. Aldosterone synthase inhibitors for resistant hypertension: pharmacological insights\u2014a systematic review. Drugs. 2025;85(11):1429\u201353. https:\/\/doi.org\/10.1007\/s40265-025-02229-2.","journal-title":"Drugs"},{"key":"817_CR16","doi-asserted-by":"publisher","unstructured":"Marzano L, Merlo M, Martinelli N, Pizzolo F, Friso S. Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review. Hypertension. 2025;82(4). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23962.","DOI":"10.1161\/HYPERTENSIONAHA.124.23962"},{"issue":"3","key":"817_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","volume":"57","author":"R Gros","year":"2011","unstructured":"Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57(3):442\u201351. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.161653. (PubMed PMID: 21242460; PubMed Central PMCID: PMC6626623).","journal-title":"Hypertension"},{"issue":"11","key":"817_CR18","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2025.09","volume":"18","author":"SK Patel","year":"2025","unstructured":"Patel SK, Teoh H, Saunthar A, Yau TM, Verma S. The emerging role of aldosterone synthase inhibitors in overcoming renin\u2013angiotensin\u2013aldosterone system therapy limitations: a narrative review. Card Fail Rev. 2025;18(11):e20. https:\/\/doi.org\/10.15420\/cfr.2025.09.","journal-title":"Card Fail Rev"},{"issue":"1","key":"817_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189\u201396. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07716. (PubMed PMID: 27872236; PubMed Central PMCID: PMC5142369).","journal-title":"Hypertension"},{"issue":"18","key":"817_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392(18):1813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2501440.","journal-title":"N Engl J Med"},{"key":"817_CR21","doi-asserted-by":"publisher","unstructured":"Turner RM, Bird SM, Higgins JPT. The impact of study size on meta-analyses: examination of underpowered studies in cochrane reviews. Gluud LL, editor. PLoS ONE. 2013;8(3):e59202. https:\/\/doi.org\/10.1371\/journal.pone.0059202.","DOI":"10.1371\/journal.pone.0059202"},{"issue":"16","key":"817_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1712231","volume":"378","author":"JR Banegas","year":"2018","unstructured":"Banegas JR, Ruilope LM, De La Sierra A, Vinyoles E, Gorostidi M, De La Cruz JJ, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378(16):1509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1712231.","journal-title":"N Engl J Med"},{"key":"817_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"7650","key":"817_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"817_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"issue":"4","key":"817_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine SL, Mathes T, Neugebauer EAM, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.11.007.","journal-title":"J Clin Epidemiol"},{"key":"817_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04726-3","author":"AA Abouelmagd","year":"2025","unstructured":"Abouelmagd AA, Ramadan S, Sayed MS, Saad OA, Yassin MN, Mostafa AM, et al. Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04726-3.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"817_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04896-0","author":"U Alam","year":"2025","unstructured":"Alam U, Rath S, Javed J, Khan AS, Moiz A, Ansab M, et al. Efficacy and safety of lorundrostat in uncontrolled hypertension: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04896-0.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"817_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jch.70155","volume":"27","author":"A Dad","year":"2025","unstructured":"Dad A, Bakht K, Tahir HB, Arham M, Goel A, Ahmad MM, et al. Efficacy and safety of lorundrostat in uncontrolled hypertension: a systematic review and meta\u2010analysis. J Clin Hypertens. 2025;27(9):e70155. https:\/\/doi.org\/10.1111\/jch.70155.","journal-title":"J Clin Hypertens"},{"issue":"5","key":"817_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70094","volume":"8","author":"JS Goh","year":"2025","unstructured":"Goh JS, Sohail S, Ayub H, Cheema ZZ, Paray NB, Adikari S, et al. Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta\u2010analysis. Endocrinol Diabetes Metab. 2025;8(5):e70094. https:\/\/doi.org\/10.1002\/edm2.70094.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"817_CR31","doi-asserted-by":"publisher","DOI":"10.5646\/ch.2025.31.e41","volume":"31","author":"A Louat","year":"2025","unstructured":"Louat A, Dwikat M, Nounou MV, Abdulhamid SM, Abdelaziz AM, Ibrahim A, et al. Efficacy and safety of selective aldosterone synthase inhibitors in uncontrolled hypertension: a systematic review and meta-analysis of randomized controlled trials. Clin Hypertens. 2025;31(1):e41. https:\/\/doi.org\/10.5646\/ch.2025.31.e41.","journal-title":"Clin Hypertens"},{"issue":"6","key":"817_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40292-025-00742-9","volume":"32","author":"M Mubeen","year":"2025","unstructured":"Mubeen M, Rai KD, Sangtiani AK, Shuaib L, Irfan A, Poudel S. Efficacy and safety of lorundrostat in uncontrolled and\/or treatment resistant hypertension: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. 2025;32(6):599\u2013615. https:\/\/doi.org\/10.1007\/s40292-025-00742-9.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"817_CR33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91681","author":"S Rasul","year":"2025","unstructured":"Rasul S, Rawat A, Mazhar M, Kumar D, Laxman A, Chaudhari SS, et al. Efficacy and safety of lorundrostat in patients with uncontrolled and treatment-resistant hypertension: a systematic review and meta-analysis. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.91681.","journal-title":"Cureus"},{"key":"817_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaf246","author":"VM Ribeiro","year":"2025","unstructured":"Ribeiro VM, Cavalcante DN, Celkevicius HET, Camacho GCG, Neves HAF, De Souza K, et al. Lorundrostat for patients with uncontrolled hypertension: a systematic review with meta-analysis and trial sequential analysis. Am J Hypertens. 2025. https:\/\/doi.org\/10.1093\/ajh\/hpaf246.","journal-title":"Am J Hypertens"},{"key":"817_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2025.107550","volume":"161","author":"L Shalabi","year":"2025","unstructured":"Shalabi L, Tawfik AM, Al Zoubi BM, Al Othman A, Zreigh S, Abuelazm M. Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: a systematic review and meta-analysis with trial sequential analysis. Vascul Pharmacol. 2025;161:107550. https:\/\/doi.org\/10.1016\/j.vph.2025.107550.","journal-title":"Vascul Pharmacol"},{"issue":"12","key":"817_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102875","volume":"49","author":"R Siddiqui","year":"2024","unstructured":"Siddiqui R, Nadeem H, Sattar MA, Rehan M, Sheikh DN, Jawed S, et al. Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta-analysis. Curr Probl Cardiol. 2024;49(12):102875. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102875.","journal-title":"Curr Probl Cardiol"},{"issue":"12","key":"817_CR37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial. JAMA. 2023;330(12):1140. https:\/\/doi.org\/10.1001\/jama.2023.16029.","journal-title":"JAMA"},{"issue":"5","key":"817_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA. 2025;334(5):409. https:\/\/doi.org\/10.1001\/jama.2025.9413.","journal-title":"JAMA"},{"issue":"12","key":"817_CR39","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/13543784.2025.2605074","volume":"34","author":"F Fogacci","year":"2025","unstructured":"Fogacci F, Borghi C, Cicero AF. Targeting aldosterone in sleep apnea: opening a new therapeutic era. Expert Opin Investig Drugs. 2025;34(12):957\u201360.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"817_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1513\/AnnalsATS.201901-053OC","volume":"16","author":"E Sapi\u00f1a-Beltr\u00e1n","year":"2019","unstructured":"Sapi\u00f1a-Beltr\u00e1n E, Torres G, Benitez I, Fortuna-Guti\u00e9rrez AM, M\u00e1rquez PP, Masa JF, et al. Prevalence, characteristics, and association of obstructive sleep apnea with blood pressure control in patients with resistant hypertension. Ann Am Thorac Soc. 2019;16(11):1414\u201321.","journal-title":"Ann Am Thorac Soc"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00817-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00817-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00817-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:45:55Z","timestamp":1787309155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00817-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00817-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the authors used claude.ai for grammar checking and language enhancement. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":6,"name":"Ethics","label":"Declaration of Generative AI and AI-Assisted Technologies in the Manuscript Preparation Process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}